Cite
HARVARD Citation
Musella, V. et al. (n.d.). Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab. International journal of cancer. 137 (6), pp. 1467-1474. [Online].